• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Guardant Health Inc.

    2/24/25 4:19:02 PM ET
    $GH
    Medical Specialities
    Health Care
    Get the next $GH alert in real time by email
    S-8 1 d929918ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on February 24, 2025

    Registration No. 333-    

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    Guardant Health, Inc.

    (Exact name of Registrant as specified in its charter)

     

     

     

    Delaware   45-4139254

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification Number)

    3100 Hanover Street

    Palo Alto, California

      94304
    (Address of Principal Executive Offices)   (Zip Code)

    2018 Incentive Award Plan

    2018 Employee Stock Purchase Plan

    (Full Title of the Plan)

    John Saia

    Chief Legal Officer and Corporate Secretary

    3100 Hanover Street

    Palo Alto, California, 94304

    (855) 698-8887

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

     

    Copies to:

    Andrew Thorpe, Esq.

    Elena Vespoli, Esq.

    Gunderson Dettmer Stough Villeneuve

    Franklin & Hachigian, LLP

    One Bush Plaza

    Suite 1200

    San Francisco, California 94104

    Tel: (415) 978-9803

    Fax: (415) 978-9806

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☒    Accelerated filer   ☐
    Non-accelerated filer   ☐    Smaller reporting company   ☐
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     


    EXPLANATORY NOTE

    This Registration Statement on Form S-8 is being filed with the Securities and Exchange Commission (the “Commission”) for the purpose of registering an aggregate of an additional 4,795,700 shares of common stock of the Registrant issuable under the following employee benefit plans for which registration statements (File Nos. 333-227762, 333-236807, 333-253733, 333-263105, 333-270241 and 333-277312) of the Registrant on Form S-8 (the “Registration Statements”) are effective: (i) the Guardant Health, Inc. 2018 Incentive Award Plan which, as a result of the operation of an automatic annual increase provision therein, added 3,689,000 shares of common stock and (ii) the Guardant Health, Inc. 2018 Employee Stock Purchase Plan which, as a result of the operation of an automatic annual increase provision therein, added 1,106,700 shares of common stock.

    INCORPORATION BY REFERENCE OF CONTENTS OF REGISTRATION STATEMENTS ON

    FORM S-8

    Pursuant to General Instruction E of Form S-8, the contents of the Registration Statements on Form S-8 filed with the Commission on October 10, 2018 (File No.  333-227762), March 2, 2020 (File No. 333-236807), March  1, 2021 (File No. 333-253733), February  28, 2022 (File No. 333-263105), March  2, 2023 (File No. 333-270241) and February  23, 2024 (File No. 333-277312) are incorporated by reference herein.


    EXHIBIT INDEX

     

    Exhibit

    Number

            Incorporated by Reference       
      

    Exhibit Description

       Form      Date      Exhibit     File
    Number
         Filed
    Herewith
      4.1    Amended and Restated Certificate of Incorporation.      8-K        10-9-18        3.1       001-38683     
      4.2    Amended and Restated Bylaws.      8-K        10-9-18        3.2       001-38683     
      5.1    Opinion of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP.               X
     10.1    2018 Incentive Award Plan.      S-8        10-10-18        99.2 (a)      333-227762     
     10.2    Form of Stock Option Agreement under the 2018 Incentive Award Plan.      10-Q        8-7-24        10.2       001-38683     
     10.3    Form of Restricted Stock Award Agreement under the 2018 Incentive Award Plan.      S-1/A        9-21-18        10.9 (b)      333-227206     
     10.4    Form of Restricted Stock Unit Award Agreement under the 2018 Incentive Award Plan.      10-Q        8-7-24        10.3       001-38683     
     10.5    Forms of Performance-Based Restricted Stock Unit Award Agreement under the 2018 Incentive Award Plan.      10-Q        8-7-24        10.4       001-38683     
     10.6    2018 Employee Stock Purchase Plan.      S-8        10-10-18        99.3       333-227762     
     10.7    First Amendment to 2018 Employee Stock Purchase Plan.      10-K        3-29-19        10.4 (a)      001-38683     
     23.1    Consent of Deloitte & Touche LLP, Independent Registered Public Accounting Firm.               X
     23.2    Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm.               X
     23.3    Consent of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP (included in Exhibit 5.1).               X
     24.1    Power of Attorney (incorporated by reference to the signature page hereto).               X
    107    Filing Fee Table.               X


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Palo Alto, California, on February 24, 2025.

     

    Guardant Health, Inc.
    By:   /s/ Michael Bell
      Michael Bell
      Chief Financial Officer

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below does hereby constitute and appoint Helmy Eltoukhy, AmirAli Talasaz and Michael Bell and each of them, with full power of substitution and full power to act without the other, his or her true and lawful attorney-in-fact and agent to act for him or her in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to file this registration statement, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in order to effectuate the same as fully, to all intents and purposes, as they or he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the date indicated.


    Signature

      

    Title

     

    Date

    /s/ Helmy Eltoukhy

    Helmy Eltoukhy

       Co-Chief Executive Officer (Principal Executive Officer) and Chairman of the Board of Directors   February 24, 2025

    /s/ AmirAli Talasaz

    AmirAli Talasaz

      

    Co-Chief Executive Officer

    (Principal Executive Officer) and Director

      February 24, 2025

    /s/ Michael Bell

    Michael Bell

      

    Chief Financial Officer

    (Principal Accounting Officer and Principal Financial Officer)

      February 24, 2025

    /s/ Ian Clark

    Ian Clark

       Director   February 24, 2025

    /s/ Vijaya Gadde

    Vijaya Gadde

       Director   February 24, 2025

    /s/ Meghan Joyce

    Meghan Joyce

       Director   February 24, 2025

    /s/ Steve Krognes

    Steve Krognes

       Director   February 24, 2025

    /s/ Manuel Hidalgo Medina

    Manuel Hidalgo Medina

       Director   February 24, 2025

    /s/ Roberto Mignone

    Roberto Mignone

       Director   February 24, 2025

    /s/ Myrtle Potter

    Myrtle Potter

       Director   February 24, 2025

    /s/ Musa Tariq

    Musa Tariq

       Director   February 24, 2025
    Get the next $GH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GH

    DatePrice TargetRatingAnalyst
    4/10/2025$55.00Outperform
    Mizuho
    1/23/2025$60.00Overweight
    Barclays
    6/28/2024$36.00Neutral → Buy
    Guggenheim
    6/3/2024$32.00Buy
    Jefferies
    4/24/2024$28.00Buy
    Craig Hallum
    12/14/2023Neutral
    Guggenheim
    12/13/2023Peer Perform
    Wolfe Research
    11/13/2023$27.00Mkt Perform → Outperform
    Raymond James
    More analyst ratings

    $GH
    SEC Filings

    See more
    • SEC Form 10-Q filed by Guardant Health Inc.

      10-Q - Guardant Health, Inc. (0001576280) (Filer)

      4/30/25 5:10:41 PM ET
      $GH
      Medical Specialities
      Health Care
    • Guardant Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Guardant Health, Inc. (0001576280) (Filer)

      4/30/25 4:11:06 PM ET
      $GH
      Medical Specialities
      Health Care
    • SEC Form DEFA14A filed by Guardant Health Inc.

      DEFA14A - Guardant Health, Inc. (0001576280) (Filer)

      4/29/25 4:35:16 PM ET
      $GH
      Medical Specialities
      Health Care

    $GH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Tariq Musa sold $4,645 worth of shares (116 units at $40.04), decreasing direct ownership by 3% to 3,479 units (SEC Form 4)

      4 - Guardant Health, Inc. (0001576280) (Issuer)

      5/20/25 4:57:58 PM ET
      $GH
      Medical Specialities
      Health Care
    • Director Tariq Musa converted options into 250 shares, increasing direct ownership by 7% to 3,595 units (SEC Form 4)

      4 - Guardant Health, Inc. (0001576280) (Issuer)

      5/19/25 7:12:29 PM ET
      $GH
      Medical Specialities
      Health Care
    • Director Potter Myrtle S converted options into 68 shares, increasing direct ownership by 0.49% to 14,063 units (SEC Form 4)

      4 - Guardant Health, Inc. (0001576280) (Issuer)

      5/19/25 7:11:17 PM ET
      $GH
      Medical Specialities
      Health Care

    $GH
    Financials

    Live finance-specific insights

    See more
    • Guardant Health Reports First Quarter 2025 Financial Results and Increases 2025 Revenue Guidance

      Revenue growth of 21% broadly driven by strong performance across oncology, screening, and biopharma & data Raises 2025 revenue guidance to $880 to $890 million, representing growth of 19% to 20% Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today reported financial results for the quarter ended March 31, 2025. First Quarter 2025 Financial Highlights For the three-month period ended March 31, 2025, as compared to the same period of 2024: Reported total revenue of $203.5 million, an increase of 21%, driven by: Oncology revenue of $150.6 million, an increase of 20%, and approximately 59,000 oncology tests, an increase of 25% Screening revenue of $5.7 milli

      4/30/25 4:05:00 PM ET
      $GH
      Medical Specialities
      Health Care
    • Guardant Health to Report First Quarter 2025 Financial Results on April 30, 2025

      Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced it will report financial results for the first quarter 2025 after market close on Wednesday, April 30, 2025. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.guardanthealth.com. The webcast will be archived and available for replay after the event. About Guardant Health Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Gua

      4/10/25 4:05:00 PM ET
      $GH
      Medical Specialities
      Health Care
    • Guardant Health Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Outlook

      Full year 2024 total revenue growth of 31% driven by strong clinical oncology volume growth, Guardant360 ASP tailwinds, and product upgrades Expects full year 2025 total revenue to be in the range of $850 to $860 million Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today reported financial results for the quarter and full year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights For the three-month period ended December 31, 2024, as compared to the same period of 2023: Total revenue of $201.8 million, an increase of 30% Reported approximately 57,300 oncology clinical tests (excluding Shield) and approximately 11,050 biopharma tests, an increa

      2/20/25 4:05:00 PM ET
      $GH
      Medical Specialities
      Health Care

    $GH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Guardant Health Inc.

      SC 13G - Guardant Health, Inc. (0001576280) (Subject)

      11/13/24 7:34:17 PM ET
      $GH
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by Guardant Health Inc.

      SC 13G - Guardant Health, Inc. (0001576280) (Subject)

      11/8/24 10:46:38 AM ET
      $GH
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Guardant Health Inc.

      SC 13G/A - Guardant Health, Inc. (0001576280) (Subject)

      7/5/24 10:32:48 AM ET
      $GH
      Medical Specialities
      Health Care

    $GH
    Leadership Updates

    Live Leadership Updates

    See more

    $GH
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more

    $GH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Guardant Health Joins Forces With Dak Prescott's Faith Fight Finish Foundation and Feist-Weiller Cancer Center's Partners in Wellness to Boost Colon Cancer Screening in Underserved Communities

      Foundation's grant to mobile cancer screening program in Louisiana allows individuals to be screened with Guardant's Shield™ blood test in their own community Mobile screening events to be held during Colorectal Cancer Awareness Month (March) throughout northern and central Louisiana Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced a collaboration with Dak Prescott's Faith Fight Finish Foundation and the mobile cancer screening program, Partners in Wellness, an initiative of LSU Health Shreveport and Ochsner LSU Health—Feist-Weiller Cancer Center, to increase colorectal cancer screening rates in northern and central Louisiana. This press release

      3/5/25 8:05:00 AM ET
      $GH
      Medical Specialities
      Health Care
    • Roberto A. Mignone Joins Guardant Health Board of Directors

      Guardant Health, Inc. (NASDAQ:GH), a pioneer in precision oncology, today announced the appointment of Roberto A. Mignone to its board of directors, effective immediately. Mr. Mignone is the Founder and Managing Partner of Bridger Management LLC, an investment management firm founded in 2000 and specializing in long-term equity strategies. "We are fortunate to welcome Roberto Mignone to our board of directors, bringing his healthcare industry expertise, long-term vision, and business acumen to our company," said Helmy Eltoukhy, chairman and co-CEO of Guardant Health. "We look forward to Mr. Mignone's perspective as we strengthen our product offerings across the continuum of care, and look

      10/24/24 5:05:00 PM ET
      $GH
      Medical Specialities
      Health Care
    • Dr. Manuel Hidalgo Medina Joins Guardant Health Board of Directors

      Guardant Health, Inc. (NASDAQ:GH), a pioneer in precision oncology, today announced the appointment of Dr. Manuel Hidalgo Medina to its board of directors, effective immediately. Dr. Hidalgo currently serves as Chief of the Division of Hematology and Medical Oncology at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center. "Dr. Hidalgo brings a wealth of expertise and leadership in translational and clinical research, particularly in anticancer drug development," said Helmy Eltoukhy, chairman and co-CEO of Guardant Health. "His extensive experience in precision oncology and his commitment to advancing oncology care make him an invaluable addition to our board." A

      7/18/24 5:00:00 PM ET
      $GH
      Medical Specialities
      Health Care
    • July 30, 2024 - FDA Roundup: July 30, 2024

      For Immediate Release: July 30, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA is announcing the fiscal year (FY) 2025 user fee rates for importers approved to participate in the Voluntary Qualified Importer Program (VQIP) and accreditation and certification bodies interested in participating in the Accredited Third-Party C

      7/30/24 3:38:18 PM ET
      $GH
      Medical Specialities
      Health Care
    • May 28, 2021 - FDA Approves First Targeted Therapy for Lung Cancer Mutation Previously Considered Resistant to Drug Therapy

      For Immediate Release: May 28, 2021 Today, the U.S. Food and Drug Administration approved Lumakras (sotorasib) as the first treatment for adult patients with non-small cell lung cancer whose tumors have a specific type of genetic mutation called KRAS G12C and who have received at least one prior systemic therapy. This is the first approved targeted therapy for tumors with any KRAS mutation, which accounts for ap

      5/28/21 1:05:48 PM ET
      $AMGN
      $GH
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Medical Specialities
    • May 21, 2021 - FDA Approves First Targeted Therapy for Subset of Non-Small Cell Lung Cancer

      For Immediate Release: May 21, 2021 Today, the U.S. Food and Drug Administration approved Rybrevant (amivantamab-vmjw) as the first treatment for adult patients with non-small cell lung cancer whose tumors have specific types of genetic mutations: epidermal growth factor receptor (EGFR) exon 20 insertion mutations. The FDA also approved the Guardant360 CDx (Guardant Health Inc.) as a companion diagnostic for Ry

      5/21/21 12:50:51 PM ET
      $JNJ
      $GH
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical Specialities
    • National Comprehensive Cancer Network (NCCN) Updates Colorectal Cancer Screening Guidelines to Include Shield Blood-Based Screening

      First national guideline recommendation for Shield paves the way for improved patient access and additional major guideline inclusions NCCN guidelines point to landmark ECLIPSE Study showing efficacy of Shield Shield is FDA-approved for adults age 45 or older at average risk for colorectal cancer Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced that the National Comprehensive Cancer Network (NCCN) has included the Shield blood test in its updated colorectal cancer (CRC) screening guidelines. The Shield test detects CRC signals in the bloodstream from DNA that is shed by tumors, called circulating tumor DNA (ctDNA). The updated NCCN CRC Scree

      6/2/25 8:05:00 AM ET
      $GH
      Medical Specialities
      Health Care
    • SERENA-6 Phase III Trial Demonstrates Clinical Value of Guardant360 CDx Test to Detect Emergence of Endocrine Resistance and Inform a Switch in Therapy Before Radiological Disease Progression in Advanced Breast Cancer

      First pivotal trial to use a circulating tumor DNA (ctDNA)-guided approach to detect and treat emerging resistance in 1st-line therapy ahead of disease progression in breast cancer Trial showed AstraZeneca's camizestrant reduced risk of disease progression or death by 56% in patients with advanced HR-positive breast cancer with an emergent ESR1 tumor mutation as detected by Guardant360 CDx Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced that the results of the Phase III SERENA-6 trial - sponsored by AstraZeneca - demonstrate the clinical value of the Guardant360® CDx test in a circulating tumor DNA-guided approach to detect and treat emerging

      6/2/25 7:00:00 AM ET
      $GH
      Medical Specialities
      Health Care
    • In Largest Molecular Residual Disease (MRD) Study in Colon Cancer, Guardant Reveal Testing Prior to Chemotherapy Provides Robust Stratification for Risk of Disease Recurrence and Survival to Enable Timely Treatment Decisions

      Data support routine use of circulating tumor DNA testing in management of stage III colon cancer patients Tumor fraction analysis provides further insights for patient management in patients with ctDNA detected Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, and its research collaborators today presented results of the largest study to date evaluating circulating tumor DNA (ctDNA) in colon cancer prior to chemotherapy, demonstrating the ability of the Guardant Reveal™ test to stratify the risk of disease recurrence and overall survival, and thus inform treatment decisions after surgery. Data from the phase III trial of FOLFOX-based adjuvant chemotherapy (NCC

      5/31/25 8:05:00 AM ET
      $GH
      Medical Specialities
      Health Care

    $GH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Mizuho initiated coverage on Guardant Health with a new price target

      Mizuho initiated coverage of Guardant Health with a rating of Outperform and set a new price target of $55.00

      4/10/25 12:41:47 PM ET
      $GH
      Medical Specialities
      Health Care
    • Barclays initiated coverage on Guardant Health with a new price target

      Barclays initiated coverage of Guardant Health with a rating of Overweight and set a new price target of $60.00

      1/23/25 7:45:30 AM ET
      $GH
      Medical Specialities
      Health Care
    • Guardant Health upgraded by Guggenheim with a new price target

      Guggenheim upgraded Guardant Health from Neutral to Buy and set a new price target of $36.00

      6/28/24 7:41:07 AM ET
      $GH
      Medical Specialities
      Health Care

    $GH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Kalia Kumud bought $38,963 worth of shares (2,187 units at $17.82), increasing direct ownership by 21% to 12,722 units (SEC Form 4)

      4 - Guardant Health, Inc. (0001576280) (Issuer)

      3/19/24 5:29:06 PM ET
      $GH
      Medical Specialities
      Health Care